Search

Your search keyword '"Bethge, Wolfgang A."' showing total 17 results
Start Over Author "Bethge, Wolfgang A." Journal bone marrow transplantation
17 results on '"Bethge, Wolfgang A."'

1. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)

Author

Niederwieser, Christian, primary, Iacobelli, Simona, additional, Franke, Georg-Nikolaus, additional, Koster, Linda, additional, van Os, Marleen, additional, Platzbecker, Uwe, additional, Hübel, Kai, additional, Scheid, Christof, additional, Müller, Lutz Peter, additional, Stelljes, Matthias, additional, Morozova, Elena, additional, Passweg, Jakob, additional, Onida, Francesco, additional, Dreger, Peter, additional, Saccardi, Riccardo, additional, Ladetto, Marco, additional, Salmenniemi, Urpu, additional, Bethge, Wolfgang, additional, Poiré, Xavier, additional, Kobbe, Guido, additional, McLornan, Donal P., additional, Robin, Marie, additional, and Kröger, Nicolaus, additional

Published
2024
Full Text
View/download PDF

2. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, primary, Labopin, Myriam, additional, Kröger, Nicolaus, additional, Finke, Jürgen, additional, Stelljes, Matthias, additional, Schroeder, Thomas, additional, Einsele, Herman, additional, Tischer, Johanna, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang, additional, Brecht, Arne, additional, Rösler, Wolf, additional, Dreger, Peter, additional, Schäfer-Eckart, Kerstin, additional, Passweg, Jakob, additional, Blau, Igor Wolfgang, additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

3. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, primary, Iacobelli, Simona, additional, Koster, Linda, additional, Eikema, Dirk-Jan, additional, van Biezen, Anja, additional, Stölzel, Friedrich, additional, Ciceri, Fabio, additional, Bethge, Wolfgang, additional, Dreger, Peter, additional, Wagner-Drouet, Eva-Maria, additional, Reményi, Péter, additional, Stelljes, Matthias, additional, Markiewicz, Miroslaw, additional, McLornan, Donal P., additional, Yakoub-Agha, Ibrahim, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

4. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT

Author

Hirschbühl, Klaus, primary, Labopin, Myriam, additional, Polge, Emmanuelle, additional, Blaise, Didier, additional, Bourhis, Jean Henri, additional, Socié, Gerard, additional, Forcade, Edouard, additional, Yakoub-Agha, Ibrahim, additional, Labussière-Wallet, Hélène, additional, Bethge, Wolfgang, additional, Chevallier, Patrice, additional, Bonnet, Sarah, additional, Stelljes, Matthias, additional, Spyridonidis, Alexandros, additional, Peric, Zinaida, additional, Brissot, Eolia, additional, Savani, Bipin, additional, Giebel, Sebastian, additional, Schmid, Christoph, additional, Ciceri, Fabio, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

5. Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Author

Bug, Gesine, primary, Labopin, Myriam, additional, Niittyvuopio, Riitta, additional, Stelljes, Matthias, additional, Reinhardt, Hans Christian, additional, Hilgendorf, Inken, additional, Kröger, Nicolaus, additional, Kaare, Ain, additional, Bethge, Wolfgang, additional, Schäfer-Eckart, Kerstin, additional, Verbeek, Mareike, additional, Mielke, Stephan, additional, Carlson, Kristina, additional, Bazarbachi, Ali, additional, Spyridonidis, Alexandros, additional, Savani, Bipin N., additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

6. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Kulagin, Alexander, Velardi, Andrea, Sanz, Jaime, Labussière-Wallet, Hélène, Potter, Victoria, Kuball, Jürgen, Sica, Simona, Parovichnikova, Elena, Bethge, Wolfgang, Maillard, Natacha, Platzbecker, Uwe, Stölzel, Friedrich, Ciceri, Fabio, and Mohty, Mohamad

Abstract

Second transplantation (HSCT2) is a potential treatment for primary graft failure (pGF). We assessed the outcome of HSCT2, performed between 2000 and 2021, for pGF in 243 patients with acute leukemia. Median age was 44.8 years. Conditioning at first HSCT (HSCT1) was myeloablative (MAC) in 58.4%. Median time from HSCT1 to HSCT2 was 48 days. Donors for HSCT2 were the same as for HSCT1 in 49%. Engraftment post HSCT2 was achieved by 73.7% of patients. The incidence of acute (a) graft versus host disease (GVHD) grades II-IV and III-IV was 23.2 and 8.1%. 5-year total and extensive chronic (c) GVHD was 22.3 and 10.1%. 5-year nonrelapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD free, relapse-free survival (GRFS) was 51.6, 18.8, 29.6, 30.7 and 22.4%, respectively. Infections were the main cause of death. In multivariable analysis, being transplanted at second vs. first remission, lower Karnofsky performance status (KPS; <90) and receiving MAC at HSCT1 were adverse prognostic factors for NRM, LFS, OS, and GRFS, as was increased age for NRM, LFS, OS. We conclude that HSCT2 can rescue about a third of the patients who experienced pGF, but NRM is as high as 50%.

Published
2023
Full Text
View/download PDF

7. Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei, Hematology, CCA - Cancer Treatment and quality of life, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, Transplantation Conditioning, MESH: Busulfan, Medizin, MESH: Graft vs Host Disease, Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, MESH: Transplantation Conditioning, Retrospective Studies, Transplantation, Acute leukemia, MESH: Humans, MESH: Middle Aged, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, MESH: Retrospective Studies, Retrospective cohort study, Hematology, Middle Aged, Total body irradiation, Fludarabine, Leukemia, Myeloid, Acute, Regimen, 030220 oncology & carcinogenesis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Leukemia, Myeloid, Acute, business, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, 030215 immunology, medicine.drug
Abstract

International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Published
2021

8. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis

Author

Rodríguez-Arbolí, Eduardo, primary, Labopin, Myriam, additional, Eder, Matthias, additional, Brecht, Arne, additional, Blau, Igor Wolfgang, additional, Huynh, Anne, additional, Forcade, Edouard, additional, Tischer, Johanna, additional, Bethge, Wolfgang, additional, Bondarenko, Sergey, additional, Verbeek, Mareike, additional, Bulabois, Claude Eric, additional, Einsele, Hermann, additional, Stölzel, Friedrich, additional, Savani, Bipin, additional, Spyridonidis, Alexandros, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Brissot, Eolia, additional, Schmid, Christoph, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

10. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

Author

Bethge, Wolfgang A., primary, Eyrich, Matthias, additional, Mielke, Stephan, additional, Meisel, Roland, additional, Niederwieser, Dietger, additional, Schlegel, Paul G., additional, Schulz, Ansgar, additional, Greil, Johann, additional, Bunjes, Donald, additional, Brecht, Arne, additional, Kuball, Jurgen, additional, Schumm, Michael, additional, Vucinic, Vladan, additional, Wiesneth, Markus, additional, Bonig, Halvard, additional, Westinga, Kasper, additional, Biedermann, Stefanie, additional, Holtkamp, Silke, additional, Karitzky, Sandra, additional, Malchow, Michaela, additional, Siewert, Christiane, additional, Handgretinger, Rupert, additional, and Lang, Peter, additional

Published
2021
Full Text
View/download PDF

11. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

Author

Bethge, Wolfgang A., Eyrich, Matthias, Mielke, Stephan, Meisel, Roland, Niederwieser, Dietger, Schlegel, Paul G., Schulz, Ansgar, Greil, Johann, Bunjes, Donald, Brecht, Arne, Kuball, Jurgen, Schumm, Michael, Vucinic, Vladan, Wiesneth, Markus, Bonig, Halvard, Westinga, Kasper, Biedermann, Stefanie, Holtkamp, Silke, Karitzky, Sandra, Malchow, Michaela, Siewert, Christiane, Handgretinger, Rupert, and Lang, Peter

Abstract

Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I/II trial of transplantation of TCRαβ and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (n= 43), myelodysplastic or myeloproliferative syndrome (n= 6), multiple myeloma (n= 1), solid tumors (n= 6), and non-malignant disorders (n= 4) were enrolled. TCR αβ/CD19-depleted grafts prepared decentrally at six manufacturing sites contained a median of 12.1 × 106CD34+cells/kg and 14.2 × 103TCRαβ+T-cells/kg. None of the patients developed grade lll/IV acute graft-versus-host disease (GVHD) and only six patients (10%) had grade II acute GVHD. With a median follow-up of 733 days 36/60 patients are alive. The cumulative incidence of non-relapse mortality at day 100, 1 and 2 years after HSCT was 5%, 15%, and 17% for all patients, respectively. Estimated probabilities of overall and disease-free survival at 2 years were 63% and 50%, respectively. Based on these promising results in a high-risk patient cohort, haploidentical HSCT using TCRαβ/CD19-depleted grafts represents a viable treatment option.

Published
2022
Full Text
View/download PDF

12. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

Author

Dreger, Peter, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner, Eva, Wulf, Gerald, Marks, Reinhardt, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Schroers, Roland, Wolff, Daniel, Thomas, Simone, Kröger, Nicolaus, and Bethge, Wolfgang A.

Published
2022
Full Text
View/download PDF

13. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Author

Dreger, Peter, primary, Michallet, Mauricette, additional, Bosman, Paul, additional, Dietrich, Sascha, additional, Sobh, Mohamad, additional, Boumendil, Ariane, additional, Nagler, Arnon, additional, Scheid, Christof, additional, Cornelissen, Jan, additional, Niederwieser, Dietger, additional, Müller, Lutz, additional, Vandenberghe, Elizabeth, additional, Scortechini, Ilaria, additional, Schoemans, Helene, additional, Andersen, Niels S., additional, Finke, Jürgen, additional, Russo, Domenico, additional, Ljungman, Per, additional, Passweg, Jakob, additional, van Gelder, Michel, additional, Durakovic, Nadira, additional, Labussiere-Wallet, Helene, additional, Berg, Tobias, additional, Wulf, Gerald, additional, Bethge, Wolfgang, additional, Bunjes, Donald, additional, Stilgenbauer, Stefan, additional, Canepari, Maria Elisa, additional, Schaap, Michel, additional, Fox, Christopher P., additional, Kröger, Nicolaus, additional, Montoto, Silvia, additional, and Schetelig, Johannes, additional

Published
2018
Full Text
View/download PDF

15. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Author

Michallet, Mauricette, Dreger, Peter, Sobh, Mohamad, Koster, Linda, Hoek, Jennifer, Boumendil, Ariane, Scheid, Christof, Fox, Christopher P., Wulf, Gerald, Krüger, William, van Gelder, Michel, Corradini, Paolo, Russo, Domenico, Passweg, Jakob, Schoemans, Hélène, Bethge, Wolfgang, Schaap, Nicolaas, Cornelissen, Jan, Browne, Paul, Durakovic, Nadira, Muller, Lutz, Montoto, Silvia, Kroger, Nicolaus, and Schetelig, Johannes

Abstract

The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35–64) and the median number of treatment lines prior to transplantation was 3 (1–10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1–140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52–84) and 50% (95% CI: 32–66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

Published
2020
Full Text
View/download PDF

16. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Author

Dreger, Peter, Michallet, Mauricette, Bosman, Paul, Dietrich, Sascha, Sobh, Mohamad, Boumendil, Ariane, Nagler, Arnon, Scheid, Christof, Cornelissen, Jan, Niederwieser, Dietger, Müller, Lutz, Vandenberghe, Elizabeth, Scortechini, Ilaria, Schoemans, Helene, Andersen, Niels, Finke, Jürgen, Russo, Domenico, Ljungman, Per, Passweg, Jakob, Gelder, Michel, Durakovic, Nadira, Labussiere-Wallet, Helene, Berg, Tobias, Wulf, Gerald, Bethge, Wolfgang, Bunjes, Donald, Stilgenbauer, Stefan, Canepari, Maria, Schaap, Michel, Fox, Christopher, Kröger, Nicolaus, Montoto, Silvia, and Schetelig, Johannes

Abstract

The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2–4 (3–4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

Published
2019
Full Text
View/download PDF

17. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.

Author

Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, and Bethge WA

Subjects
Humans, T-Lymphocytes, Antigens, CD19, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse therapy
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results